August 31st 2020
Ruth O’Regan, MD, discusses the utility of CDK4/6 inhibitors in breast cancer.
August 14th 2020
Ruth O’Regan, MD, discusses emerging CDK4/6 inhibitor combinations in breast cancer.
July 31st 2020
Ruth O’Regan, MD, discusses biomarkers of response to CDK4/6 inhibitors in breast cancer.
December 19th 2019
Ruth O’Regan, MD, discusses patient education as biosimilars are implemented into practice for breast cancer.
November 9th 2019
Ruth O’Regan, MD, discusses the prognostic value of pathologic complete response in HER2-positive breast cancer.
December 11th 2018
Ruth O’Regan, MD, division head, Hematology and Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, discusses the role of chemotherapy as treatment continues to advance in breast cancer.
November 22nd 2018
Ruth O’Regan, MD, division head, Hematology and Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, discusses the impact of targeted agents in HER2-positive breast cancer.
October 29th 2018
Ruth O’Regan, MD, division head, Hematology and Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, discusses biosimilar education in oncology.
October 17th 2018
Ruth O’Regan, MD, division head, Hematology and Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, discusses the status of biosimilars in oncology.
October 27th 2017
Ruth O’Regan, MD, division head, Hematology and Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, discusses biomarker research in breast cancer.